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Background/aim: Giant cell arteritis (GCA) is a large vessel vasculitis that may cause significant morbidity in the elderly population.
We aimed to evaluate presentation characteristics, treatment, and outcome in a cohort of patients with GCA diagnosed and followed
in a single center.
Materials and methods: A retrospective chart review revealed 84 (41 M/43 F) registered patients diagnosed with GCA between 1990
and 2020. Clinical features at presentation and follow-up, radiographical imaging, temporal artery biopsy (TAB), and laboratory findings were retrieved from digital medical records or hard-copy patient files. Of these, 33 patients’ follow-up period was less than 12
months; hence, relapses and treatment outcomes were examined in the remaining 51 (60.5%) patients.
Results: A total of 84 patients were included in the cohort. The mean age at diagnosis was 68.4 ± 7.9 years (range: 49–85). At presentation, 60 (71.4%) patients had headache, 22 (26.2%) had symptoms compatible with polymyalgia rheumatica (PMR), and 23 (27.4%)
had visual loss. Three (3.6%) patients had solid organ malignancies while two had hematologic malignancies (2.4%) before GCA
diagnosis. TAB was obtained in 63 (75%) patients, in 47 of whom (74.6%) the pathological findings were consistent with GCA. A PET/
CT scan has been performed before glucocorticoids (GCs) initiation in 43 (51.2%) patients and of these, 37 (86.0%) revealed uptake
consistent with large vessel involvement. The median follow-up time of the 51 patients was 3.7 (IQR: 1.8–6.8) years. GCs were started
promptly after the diagnosis. During the follow-up period, 28 (54.9%) patients experienced a relapse. Thirty-nine (78%) patients were
under GC treatment, with a mean dosage of 4.8 ± 2.8 g/day at the final visit. At the final visit, 20.3% (17:84) had died whereas 9.8%
(5:51) had permanent vision loss.
Conclusion: Treatment of GCA is challenging. GCA causes serious morbidities and increased mortality. PET/CT is highly effective in
detecting large vessel vasculitis in GCA and could perhaps replace TAB in the future.
Key words: Giant cell arteritis, polymyalgia rheumatica, PET-CT, temporal artery biopsy, headache

1. Introduction
Giant cell arteritis is a large vessel vasculitis which may
cause significant morbidity such as blindness and stroke
[1]. The disease affects predominantly cranial arteries
derived from the carotid arteries. The etiology of GCA
is not clearly understood. T-cells, macrophages, and
giant cells can be seen along with granulomatous lesions
while histopathology disclosed intimal hyperplasia and
destruction of elastic fibers in involved vessel wall [2].
GCA predominantly affects European populations
especially those of Scandinavian origin (>20/100,000
people older than 50 years) [3,4] in comparison with the
Southern European and Mediterranean races (Turkey and
Tunisia: ~1.13–7/100,000 people older than 50 years) [5-8].

GCA cases usually present with cranial ischemic
manifestations such as headache, visual symptoms, jaw
claudication, and tense and swollen temporal arteries.
Some may present with symptoms compatible with
polymyalgia rheumatica (PMR) as well [9].
The diagnosis of the GCA should be based on
typical clinical findings, elevated acute phase reactants,
panarteritis in temporal artery biopsy (TAB), and large
vessel involvement in imaging modalities [10,11]. Recently,
PET-CT, a noninvasive technique, offers considerable
benefit in the diagnosis of GCA with high sensitivity and
specificity rates compared to other radiographical imaging
modalities [12,13].
Glucocorticoids (GCs) are the mainstay in the
management in GCA. Relapses occur frequently during
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the disease course [14]; therefore, the cumulative amount
of the GCs is increased. Chronic use of GCs increases
the risk of numerous comorbid conditions, including
avascular necrosis, osteoporosis, fracture, infections, and
cardiovascular disease. Large-vessel manifestations are
well defined and include permanent vision loss, cranial
arterial occlusions, stroke, aortitis, aortic dilatation/
aneurysms or aortic dissection [15]. Although previous
studies reported that mortality rates of GCA patients are
similar to that found among healthy population [16,17],
more recent studies disclosed an increased mortality
especially in the first years of disease after the diagnosis
[18,19]. Indeed, two different metaanalyses which
underlined the mortality rates of GCA patients are similar
to general population [20,21].
We evaluated presentation characteristics, diagnostic
features, clinical outcomes, relapse frequency, and side
effects of GC therapy among patients with GCA followed
in a single tertiary institution.
2. Materials and methods
We identified 84 patients (41 M/ 43 F) who were
diagnosed with GCA at the Cerrahpaşa Medical Faculty
Rheumatology Department at İstanbul UniversityCerrahpaşa, between April 1990 and December 2020.
The diagnosis of GCA was made between 1990 and 2000
in 8 (9.5%), between 2000 and 2010 in 13 (15.5%), and
between 2010 and 2020 in 63 (75%) patients. Seventy-five
patients (89.3%) had fulfilled the inclusion criteria of 1990
American College of Rheumatology for GCA [10]. The
remaining nine (11.7%) patients fulfilled two diagnostic
criteria and additional active vasculitis features. Three of
these nine had presented with acute vision loss in whom
fundoscopic examination revealed arteritic ischemic optic
neuropathy. The remaining eight patients had elevated
acute phase reactants and signs of active large vessel
vasculitis in the positron emission tomography-computed
tomography (PET-CT) scan. PET-CT was started to
be used routinely after 2010 in our institution. Clinical
features and laboratory data as well as demographics,
comorbid conditions (diabetes mellitus, hypertension),
presentation symptoms, physical examination and
histopathologic findings of the 84 patients were retrieved
from digital medical records and hard-copy patient files.
Of these 84 patients, 33 (39.3%) had a follow-up period of
less than 12 months while the remaining 51 (60.7%) had
been regularly followed more than a year at the outpatient
clinic. Treatment modalities, relapses, and outcomes were
analyzed in these 51 (24 M/27 F) patients.
Relapse was defined similar to what had been published
previously [14], the patient status that required an increase
in the drug doses or switching to a new therapy, and was
1

classified in the following groups: a) a new or preexisting
sign/symptom with simultaneous increase of either CRP or
ESR was observed, b) a new or preexisting sign/symptom
without any increase in acute phase reactants, and c) acute
phase reactants were increased alone without any new
signs/symptoms of GCA or another organic etiology. The
biochemically proven relapse was defined by at least one of
the following conditions [14]: CRP level > 5mg/L (normal:
0–5 mg/L) and/or ESR by the Westergren method >22
mm/h for men and >29 mm/h for women. Deaths were
examined by Turkish Death Notification System1, a webbased software of Turkish Ministry of Health.
2.1. Statistical analysis
The normality of data was assessed using the Shapiro–
Wilk test. Median values (25th percentile–75th percentile)
were used for analysis of nonparametric data; Student’s
t-test was performed for parametric data.
Chi-squared test was used for categorical variables.
A p-value less than 0.05 was considered significant. The
survival rate was analyzed using the Kaplan–Meier plot.
Statistical analysis was performed with SPSS 20.0 software
(IBM Corp., Armonk, NY, USA).
3. Results
A total of 84 patients (41 M/ 43 F) were included in the cohort.
The mean age at diagnosis was 68.4 ± 7.9 years (range: 49–85).
Clinical and laboratory manifestations at presentation are
presented in Table 1.
3.1. Clinical characteristics at presentation and diagnostic
modalities among 84 patients
Sixty patients (71.4%) had presented with headache which
was the leading initial complaint. Twenty-three (27.4%) had
visual loss, 20 (23.8%) had jaw claudication, 19 (22.6%) had
tenderness on the temporal area, and 22 (26.2%) had PMR
symptoms. Twenty-five patients (29.8%) had fever, of whom
4 (16%) were diagnosed with fever of unknown origin at first.
TAB was obtained in 63 (75%) patients, in 47 of whom (74.6%)
the pathological findings were consistent with GCA. PET/
CT scan was performed before GCs initiation in 43 (52.4%)
patients and disclosed signs of diffuse large vessel vasculitis
in 37 (86.0%) of these patients while aortic involvement was
observed in 26 (60.5%) patients. Diagnostic performances
of the TAB and PET-CT in the present study are depicted in
Figure 1.
3.2. Comorbid conditions among 84 patients
Hypertension and diabetes mellitus were observed at
the time of GCA diagnosis in 42 (50%) and 22 (26.2%)
patients, respectively. Three (3.6%) patients had solid organ
malignancies while two had hematologic malignancies
(2.4%) before GCA diagnosis. Diagnosis of GCA and chronic
myelomonocytic leukemia was concomitantly found in one
patient, as we have previously reported [22].
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3.3. Acute phase response, medical treatment and its
complications among 51 patients
As depicted in Table 2, we evaluated treatment modalities
and outcomes in 51 patients (24 M/27 F) who were regularly
followed for at least 12 months. Median duration of followup of was 3.7 (IQR: 1.8–6.8) years. The median values of ESR
and CRP at the diagnosis were 91.6 mm/h (IQR: 68.7–112.7)
and 60 mg/L (25–111.5), respectively. These were found to be
significantly lower by the time of final evaluation (ESR: 12.5
mm/h; IQR: 9–27.5 and CRP: 3 mg/L; IQR: 1.3–6.2) (for both
ESR and CRP, p = 0.001).
GCs were initiated promptly following the diagnosis in
all patients except one. Pulses of GC were preferred in 12
(23.5%) patients and oral GCs were used in the remaining
38 (76.5%) patients with a daily mean 45.8 ± 21.3 mg GC
treatment. GCs were tapered to <5 mg/day in 28 (55.1%)
patients within the first year, in 14 (28.5%) within the
second year, and in 8 (16.3%) within the 5 years since the
initial visit. After the initiation of GCs, the median time
for tapering GC ≤5 mg/day was 8 months (IQR: 5–14.5
months). In 11 (22%) patients, GC therapy was terminated
after a median duration of 23 months (IQR: 16.7–39 months)
while 39 (78%) patients were under GC therapy with a mean
duration of 4.8 ± 2.8 g/day at the final visit. Azathioprine
(AZA) and methotrexate (MTX) were started in addition to
GC while tapering GCs in 5 (10%) and 22 (43.1%) patients,
respectively. Two patients (2:5) had to stop AZA because of

gastrointestinal intolerance and pulmonary aspergillosis.
The remaining 3 patients were still receiving AZA. MTX
was discontinued in nine patients (6:22; 27.3%) due to the
gastrointestinal intolerance (n = 2), myelosuppression (n =
2), pneumonitis (n = 1), genital herpes simplex infection (n
= 1) and alopecia (n = 1). Moreover, in three patients (3:22)
MTX was stopped after clinical and biochemical remission
(Table 3). The remaining 12 patients were still receiving
MTX.
A total of 9 patients were treated with tocilizumab (TCZ)
after 2014. TCZ was given to eight GC-dependent patients
after their first flare and to one patient who could not continue
1 mg/kg daily GCs because of the patient’s severe diabetic
condition. Except one, clinical remission and laboratory
improvement was observed in these patients during the TCZ
therapy (Table 3). GCs were safely lowered during the TCZ
treatment and four of these patients were able to stop using
GCs at the final visit (Table 3). Seven of these nine patients
were still receiving TCZ. One patient who had sustained
remission with TCZ for 44 months was discontinued the
therapy and relapse did not occurr after 1 year follow-up. The
patient who had relapse with TCZ was switched to 100 mg
daily anakinra, after 6 months during which he received TCZ,
however, continued to have relapses. This patient responded
to anakinra injections quickly and remained in remission
for 4 years. Currently, he is asymptomatic and is receiving
anakinra 100 mg every other day.

Table 1. Demographic and clinical characteristics at presentation and laboratory manifestations among 84 patients.
Age, mean ± SD, years

68.4 ± 7.9

Male, n (%)

41 (48.9)

Fulfilled ³3 GCA ACR criteria, n (%)

75 (89.3)

Temporal artery biopsy, n (%)

63 (75)

Biopsy–proven GCA, n (%)

47 (74.6)

PET-CT scan, n (%)

44 (52.6)

PET-CT–proven large vessel vasculitis, n(%)

38 (86.4)

Comorbidities, n (%)
Diabetes

22 (26.2)

Hypertension

42 (50)

Clinical symptoms, n (%)
Headache

60 (71.4)

Jaw claudication

20 (23.8)

PMR

22 (26.2)

Vision loss

23 (27.4)

Fever

25 (29.8)

Laboratory
ESR, median (IQR), mm/h

91.6 (68.7–112.7)

CRP, median (IQR), mg/L

60 (25–111.5)
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84 GCA patients

TAB performed without PET-CT

Both TAB and PET-CT performed

n= 36

n= 27

Biopsy confirmed GCA

Large vessel involvement

n= 19 (70.4%)

Neither TAB not PET-CT performed

PET-CT performed without TAB

n= 5

n= 16

Biopsy confirmed GCA

n=23 (85.2%)

n= 28 (77.7%)

Large vessel involvement
n=14 (87.5%)

Figure 1. Diagnostic performances of the temporal artery biopsy and PET-CT in 84 GCA patients, TAB
temporal artery biopsy, PET-CT positron emission tomography.
Table 2. Treatment modalities and outcomes of the 51 patients.
Figure 1. Diagnostic performances of the temporal artery biopsy and PET-CT in 84 GCA patients, TAB temporal artery biopsy, PET-CT

Characteristicpositron emission tomography

Value

Follow-up duration, median (IQR), years

3.7 (1.8–6.8)

Initial treatment
Pulse dose steroid, n (%)

12 (23.3)

Initial prednisone dose, mean (S.D), mg/day

45.8 ± 21.3

GCs tapered to <5 mg/day, n (%)
within 1st year

28 (55.1)

within 2nd year

14 (28.5)

within until 5 years

8 (16.3)

Relapse, n (%)
no relapse

23 (45.1)

one relapse

25 (49.0)

two relapses

1 (2.0)

three relapses

2 (3.9)

Vision loss, n (%)*

15 (29.4)

Outcome of the vision loss after the treatment, n (%)
complete remission

5 (35.7)

partial remission

4 (28.6)

permanent vision loss

5 (35.7)

* One patient was lost to follow-up due to complications following hip fracture and therefore could not be evaluated.

GC-associated osteoporosis, hypertension, and
diabetes were observed in 11 (21.6%), 8 (15.7%) and 4
(%7.8) patients, respectively. Additionally, two patients
(3.8%) had genital herpes, and two were admitted for
pneumonia during the treatment course that turned into
nocardiosis and aspergillosis. One patient had cutaneous
herpes zoster during the TCZ treatment.
3.4. Flares and outcomes in 51 patients
Among 51 patients who were regularly followed, 15
(29.4%) had vision loss, 14 (27.4%) presented with PMR,
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and 25 (50.1%) of all 26 patients who were evaluated with
PET-CT had large vessel vasculitis at initial visit. By the
time of final evaluation, of the 15 patients with initial
vision loss, five (35.7%) had complete remission, four
(28.6%) had a partial remission, whereas five (35.7%) had
permanent vision loss (one bilateral, four unilateral), and
the remaining one patient was lost to follow-up due to
complications following hip fracture and therefore could
not be evaluated.
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Table 3. Clinical and laboratory characteristics of the GCA patients prior and post TCZ therapy.

Characteristic

Pre-TCZ
(n = 9)

Post-TCZ
(n = 9)

Age at diagnosis, median (IQR), years

67 (65–69.5)

N/A

Disease duration prior TCZ, median (IQR), months

16 (4.5–18)

N/A

p-value

Symptoms, n (%)
Constitutional symptoms

7 (77.8)

0

N/A

Headache

1 (11.1)

0

N/A

Any visual disturbance

1 (11.1)

1 (11.1)

0.99

Comorbidities, n (%)
Hypertension

5 (55.6)

N/A

Diabetes

6 (66.7)

N/A

Laboratory
CRP, median (IQR), mg/L

10 (4.4–22)

2.9 (0.3–2.1)

0.02

ESR, median (IQR), mm/h

46 (21–59)

9 (4–14)

0.001

Prednisolone use, n (%)

9 (100)

5 (55.5)

N/A

Prednisolone dose, median (IQR), mg/day

15 (8.7–17.5)

4 (2.5–12.5)

0.001

Methotrexate use, n (%)

4 (44.4)

1 (11.1)

0.11

GCA giant cell arteritis, TCZ tociluzumab, ESR erythrocyte sedimentation rate, CRP c-reactive protein

During a median follow-up of 3.7 years, a total of 28
patients (54.9%) relapsed. Twenty-five patients (49.0%)
had one relapse, one had two relapses, and two had three
relapses. Fourteen (50.0%) patients relapsed within the
first year following the diagnosis, nine (32.1%) within
the second and third years, and five (17.9%) patients
within fourth and fifth years. Nineteen of the first relapses
(76.0%) were attributed to only laboratory abnormalities,
three (6.0%) were diagnosed with positive symptoms only,
and six (12.0%) were due to the presence of abnormal
laboratory studies in the setting of positive symptoms. Of
these 28 patients who relapsed, four were not using GC
while the remaining 24 were using GCs with a mean dose
of 5.0 ± 3.2 mg/day.
3.5. Survival rate of the 84 patients
By the end of the analysis, 17 (20.3%) of 84 patients had
died. We could not determine the exact time of death in
seven of these 17 patients. The remaining 10 patients had
died after median 8.5 (IQR: 0.9–14.7) years of follow-up,
while mortality causes were not determined. The survival
rate of the 84 GCA patients is depicted in Figure 2.
4. Discussion
In this study, we evaluated the clinical manifestations,
relapse rates, and outcomes of GCA in 84 patients (41
M/43 F) diagnosed and followed between 1990 and 2020.

Our study suggests PET-CT is a valuable vascular imaging
modality in GCA and highly effective (37:43, 86.0%) in
detecting large vessel vasculitis.
It is well known that the most frequent clinical features
of GCA are headache, ischemic manifestations, PMR, and
temporal artery swelling [15]. While most of the clinical
manifestations observed in the present study were similar
with the reported series in the literature [16], some clinical
features were relatively different. The frequency of vision
loss in our study (27.4%) was in line with that reported
previously (23%–28%) [23-25]. On the other hand, we
observed a considerably lower frequency (26.2%) of
PMR compared to other series (40%–73.7%) [8,9,26].
Deafness or stroke was not observed in any patients
during the present study; in fact, these were well-defined
intracranial manifestations of the disease [27]. Also, limb
claudication was not observed as an initial presenting
symptom which is also a rare but well-defined symptom
[15]. These differences could be due to several reasons: a)
a considerable portion of the patients was lost to follow-up
in our series which may have impacted our results, b) the
frequency and severity of GCA could be decreased in the
Mediterranean region, c) those who presented with stroke,
deafness, or other neurologic complaints had been taken
care elsewhere and hence are not referred to rheumatology
properly.
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Figure 2. Kaplan–Meier survival plot of the 84 GCA patients*. *The exact dates of death were not determined in
7 out of 17 patients; therefore, these seven patients’ last visit dates were accepted as exact time of death.

TAB used to be the gold standard in the diagnosis of
GCA [28]; however, there are a number of problems with
it, as previously reported: a) False-negative results with
TAB are not rare [29,30], b) there are technical issues such
as the length and localization [31-33], c) the timing of the
biopsy after treatment initiation is also a controversial
issue [34,35], and d) the necessity also is argued since it
is an invasive procedure [36]. This situation emphasized
the need of more accurate imaging modalities for the
diagnosis. PET-CT was found to be more accurate for
detecting large vessel involvement. Moreover, it could be
able to differentiate malignancy in elderly patients who
presented with constitutional symptoms. A metaanalysis
disclosed that the sensitivity and specificity of PET-CT in
GCA diagnosis was 90% and 98% respectively [37]. In our
study, the sensitivity of the PET-CT was found as 86.0%
(37:43) and that of TAB was calculated as 74.6% (47:63)
which were in line with what had been reported previously.
The aortic aneurysm/dissection was the most fearful
complication during the disease course. In a prospective
study, of the 54 GCA patients who had biopsy-proven
GCA, 22.2% had aortic dilatation/aneurysm during the
follow-up [38]. Another retrospective study in 130 GCA
patients revealed that those who had vascular FDG
uptake at initial PET-CT were more prone to develop
aortic complications during the follow-up [39]. These
data indicate that screening GCA patients initially with
PET-CT would be useful in order to estimate large vessel
complications during the follow-up. In our current study,
although our sample size was small and duration of
follow-up was rather short, we did not observe any aortic
aneurysm or dissection in those patients who had large
involvement in their PET-CT scan.
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Although GCs are the mainstay therapy for GCA, their
starting dose, the rate of reduction, and total duration of
therapy are not standardized. GC-related side effects are
troublesome and occur frequently during the follow-up. In
our study, osteoporosis was the most common GC-related
side effect similar to previous reports [12,40].
There is an ongoing debate whether there is a
link between GCA and malignancy. Ungprasert et al.
disclosed a notably increased risk of malignancy among
the GCA patients in a metaanalysis [41]. However, a
recent Swedish population-based study showed that there
was no increased risk of malignancy except leukemia
[42]. Additionally, Mekinian et al. showed that systemic
vasculitis was significantly more common than the other
autoimmune or inflammatory disorders among the
chronic myelomonocytic leukemia patients [43]. In the
present study, we also observed considerable number of
patients with concomitant solid organ or hematologic
malignancies prior to GCA diagnosis.
The Giant Cell Arteritis Actemra (GiACTA) trial
showed the efficacy of TCZ in patients with GCA [11]. In
the current study, eight steroid-dependent patients were
treated with TCZ. Eight of these patients received TCZ
after their first flare. Additionally, one severe diabetic
patient was treated with TCZ plus low dose GCs. Except
one, all were successfully treated with TCZ. The one who
relapsed under TCZ was switched to anakinra. Since then,
the patient remained in sustained remission. Anakinra
has limited data in the literature; it has been shown to
provide remission in 3 patients who had been refractory to
conventional treatment [44].
Published data on mortality among patients with GCA
reveals slight increase of mortality rate in this patient
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population compared to normal population especially in
the first years after the GCA diagnosis [18,19]. Ben Shabat
et al. showed that the mortality was significantly increased
over the first 2 years after the diagnosis particularly among
those £70 years [18]. However, survival rate was not found
to be impaired with longer follow-up of GCA [45]. An
increased mortality rate was significantly associated with
large vessel involvement [46]. In our study, we found that
the mortality rate was 20.3% (17:84). Yet, we think the
mortality rate we found should not be underestimated.
This study has several limitations. The number of
patients who were lost to follow-up or those with a followup duration shorter than 12 months was large. We were
unable to determine the exact time of death or the cause
of death. Lack of standardization of diagnostic modalities
was another limitation of the study. Moreover, since other
related departments such as ophthalmology and neurology
did not participate in the study, our study might not have
represented the true number of causalities.
In conclusion, PET/CT is highly effective in detecting
large vessel vasculitis in GCA and could perhaps replace

TAB in the future. Side effects of GCs are frequent.
Moreover, patients frequently had side effects during the
MTX or AZA treatments. Biological treatment seems to be
beneficial, and its widespread use should be encouraged.
Finally, GCA is a serious disease with significant morbidity
and mortality.
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